BioInvent to use Merck's bioreactors to expand Swiss facility

BioInvent International AB, a Swedish company that develops novel immuno-regulatory antibodies to treat cancer, is upgrading and expanding its drug manufacturing facility with a full line of Merck’s Mobius single-use bioreactors.

BioInvent will add bioreactors of 3, 50, 200 and 1000 litres to its upstream facility in Lund, Sweden, expanding capacity and improving flexibility and scalability. Merck’s portfolio of 3 to 2000 litres single-use Mobius bioreactors offers greater flexibility & continuity for scale-up and reduces the need for re-training of operators during scale-up processes.

“Our complete portfolio of single-use technologies addresses the needs of both emerging biopharmaceutical companies and established drug developers like BioInvent as they seek to increase productivity. We are providing a full range of bioreactors, services and support which will help BioInvent accelerate innovative therapeutics through the development pipeline,” said Udit Batra, member of the Merck executive board and CEO of the life science business sector of Merck.